CXCL 6‐EGFR‐induced Kupffer cells secrete TGF‐β1 promoting hepatic stellate cell activation via the SMAD 2/BRD 4/C‐MYC/EZH 2 pathway in liver fibrosis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is the excessive accumulation of extracellular matrix proteins in response to the inflammatory response that accompanies tissue injury, which at an advanced stage can lead to cirrhosis and even liver failure. This study investigated the role of the CXC chemokine CXCL 6 (GCP‐2) in liver fibrosis. The expression of CXCL 6 was found to be elevated in the serum and liver tissue of high stage liver fibrosis patients. Furthermore, treatment with CXCL 6 (100 ng/mL) stimulated the phosphorylation of EGFR and the expression of TGF‐β in cultured Kupffer cells (KC s). Although treatment with CXCL 6 directly did not activate the hepatic stellate cell (HSC) line, HSC‐T6, HSC s cultured with media taken from KC s treated with CXCL 6 or TGF‐β showed increased expression of α‐SMA, a marker of HSC activation. CXCL 6 was shown to function via the SMAD 2/BRD 4/C‐MYC/EZH 2 pathway by enhancing the SMAD 3‐BRD 4 interaction and promoting direct binding of BRD 4 to the C‐MYC promoter and CMY‐C to the EZH 2 promoter, thereby inducing profibrogenic gene expression in HSC s, leading to activation and transdifferentiation into fibrogenic myofibroblasts. These findings were confirmed in a mouse model of CC l 4‐induced chronic liver injury and fibrosis in which the levels of CXCL 6 and TGF‐β in serum and the expression of α‐SMA, SMAD 3, BRD 4, C‐MYC, and EZH 2 in liver tissue were increased. Taken together, our results reveal that CXCL 6 plays an important role in liver fibrosis through stimulating the release of TGF‐β by KC s and thereby activating HSC s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis contributes to the pathogenesis of a number of chronic disorders affecting the liver, kidney, lungs and heart, which collectively account for a substantial proportion of disease‐related mortalities in developed countries.(28) Despite recent FDA approval of the first antifibrotic therapies, alternative treatme…”
BackgroundRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver
Du, K., Herzig, S., Kulkarni, R. N., & Montminy, M. (2003) · Science · doi:10.1126/science.1079817 · Cited by 842
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677 · cited 1×
“Although reversible if the source of the injury is eliminated, unchecked liver fibrosis can develop into cirrhosis and even liver failure due to portal hypertension, with the only treatment option being transplantation.(1,2) Chronic liver disease is a major cause of mortality worldwide and correlates with an increased…”
BackgroundClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
The role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
Dambach, D. M., Watson, L. M., Gray, K. R., Durham, S. K., & Laskin, D. L. (2002) · Hepatology · doi:10.1053/jhep.2002.33162 · Cited by 289
Wehr, A., Baeck, C., Heymann, F., Niemietz, P. M., Hammerich, L., Martin, C., Zimmermann, H. W., Pack, O., Gassler, N., Hittatiya, K., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202909 · Cited by 268 · cited 1×
“Chemokines reported to be released by KCs include CXCL1, CXCL2 and CXCL8, which attract neutrophils,(32) CCL1, CCL2, CCL25 and CX3CL1, which promote the infiltration of bone marrow−derived monocytes,(33-36) and CXCL16, which attract natural killer T cells.(37) We therefore speculate that activated KCs may be the sourc…”
BackgroundKarlmark, K. R., Zimmermann, H. W., Roderburg, C., Gassler, N., Wasmuth, H. E., Luedde, T., Trautwein, C., & Tacke, F. (2010) · Hepatology · doi:10.1002/hep.23894 · Cited by 249
Dominguez, M., Miquel, R., Colmenero, J., Moreno, M., García–Pagán, J., Bosch, J., Arroyo, V., Ginès, P., Caballería, J., & Bataller, R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.056 · Cited by 238
BRD4 is a novel therapeutic target for liver fibrosis
Ding, N., Hah, N., Yu, R. T., Sherman, M. H., Benner, C., Leblanc, M., He, M., Liddle, C., Downes, M., & Evans, R. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522163112 · Cited by 211 · cited 7×
“BRD4 is a global regulator of enhancer−mediated profibrogenic gene expression in HSCs.(15) There is evidence from various cancer cell types that BRD4 can interact with the C-MYC promoter and directly regulate its transcriptional expression.”
BackgroundInfluentialKupffer cells mediate leptin-induced liver fibrosis
Wang, J., Leclercq, I., Brymora, J. M., Xu, N., Ramezani–Moghadam, M., London, R. M., Brigstock, D., & George, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.011 · Cited by 210 · cited 1×
“Furthermore, recent studies by one research group into the role of BRD4 in bladder cancer reported that BRD4 positively regulates enhancer of zeste homologue 2 (EZH2) transcription through the upregulation of the C-MYC promoter.(19,20) In this study, the role of CXCL6 (GCP‐2) in liver fibrosis was investigated.”
Background
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“They demonstrated that CXCL6 plays an important role in liver fibrosis through stimulating the release of TGF-β by Kupffer cells via an EGFR-dependent pathway [91].”
BackgroundTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Lee, S. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2584495 · Cited by 8
Metadata
- Authors
- Cai, X., Li, Z., Zhang, Q., Qu, Y., Xu, M., Wan, X., & Lu, L.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2018-08-14
- Volume
- 22
- Issue
- 10
- Pages
- 5050-5061
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2886268494
- Cited by
- 111
- References
- 14
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.